Pre-Open Stock Movers 01/22: (AKCA) (ACMR) (SPCE) Higher; (FCEL) (NVAX) (BPMC) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro improve AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
Applied Therapeutics Inc. (APLT) Prices 2.74M Share Upsized Common Offering at $45.50/Sh
January 24, 2020 5:43 AM ESTApplied Therapeutics, Inc. (NASDAQ: APLT) today announced the pricing of its public offering of 2,741,489 shares of its common stock, par value $0.0001 per share, at a price to the public of $45.50 per share. The gross proceeds to the Company from the offering, before deducting the underwriting discounts and commissions and estimated offering... More
Cantor Fitzgerald Reiterates Overweight Rating on Johnson & Johnson (JNJ) Following 4Q
January 23, 2020 6:39 AM ESTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $168.00 price target on Johnson & Johnson (NYSE: JNJ) following the company's 4Q earnings report. Chen continues to believe that upward earnings revisions to JNJ's Pharma business and multiple expansion, driven by diminishing headlines... More
Blueprint Medicines (BPMC) Prices 4.71M Share Common Offering at $69/Sh
January 23, 2020 5:53 AM ESTBlueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the pricing of an underwritten public offering of 4,710,144 shares of its common stock at a public offering price of $69.00 per share, before underwriting... More
UPDATE: UBS Resumes Tesla (TSLA) at Sell
January 23, 2020 4:35 AM EST(Updated - January 23, 2020 6:50 AM EST)
(updating comment)
UBS analyst Colin Langan raised the price target on Tesla (NASDAQ: TSLA) to $410.00 (from $160.00) while maintaining a Sell rating as he resumes coverage of the auto maker.
The analyst comments "We take... More



